Gender-specific nomogram models to predict the prognosis of male and female lung adenocarcinoma patients: a population-based analysis

Wen, H. Joseph; Lin, Xuefeng; Sun, Di

doi:10.21037/atm-21-5367

Cited by 7 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some clinical factors, such as gender, age, histological subtype and surgery, are related to survival of metastatic lung AD. [ 8 , 9 ] However, these elements are in ignorance of the location and quantity of organ metastatic sites. Approximately 57% of lung AD have advanced to metastatic diseases, and the prognosis of patients is adversely affected by organ metastasis.…”

Section: Introductionmentioning

confidence: 99%

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

The effect of various metastases patterns on the prognosis of lung adenocarcinoma (AD) remains unknown. The purpose of our retrospective study is to determine whether various metastases patterns have a prognostic impact on patients with organ metastatic lung AD. Patient data was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan–Meier method was chosen for the evaluation of overall survival (OS) rate. Univariable and multivariable Cox regression analyses were conducted to evaluate independent prognostic factors. In the SEER database, 12,228 patients with IV lung AD were retrieved in total. And 78.78% of those patients (9633/12,228) suffered from one of brain, lung, liver or bone metastasis due to disease progression. It was found that the most common site in patients with metastatic lung AD was brain (21.20%), and the least common site of metastasis was liver (3.50%). Patients who suffered single lung metastatic showed relatively good OS, and the median survival time was 11 months (95% CI 0.470–0.516). For those with 2 metastatic sites, data analysis suggested that the median survival times of patients with bone and lung metastasis (10 months; 95% CI 0.469–0.542) were better than others. For those with 3 metastatic sites, data analysis suggested that metastatic pattern had no effect on the OS. Brain is the most common single metastasis site of lung AD. Compared with the other 3 metastatic sites, patients with lung metastasis had better survival results. Deeper knowledge of metastatic patterns will help doctors to better understand the prognosis and formulate more appropriate treatment plans.

show abstract

Section: Introductionmentioning

confidence: 99%

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It has been reported that marital status was a protective factor for survival among patients with lung cancer [ 55 , 56 ]. The married patients in our study included married couples and those living with domestic partners, and singles were defined as single, widowed, divorced, and separated patients, which was a more detailed definition than previous studies [ 56 , 57 ]. We highlighted the potentially significant social impact of marital status on the survival of LUAD patients.…”

Section: Discussionmentioning

confidence: 99%

“…40 (1) 18149 (72) 25170 ( 100) 9273 ( 37) 13072 (52) 4505 ( 18) 6576 (26) 1483 ( 6) 2825 (11) 373 ( 1 40) 1470 (56) 514 ( 19) 732 (28) 141 ( 5) 308 ( 12 39) 9473 (54) 3325 ( 19) 4775 (27) 1095 ( 6) 2110 ( 12 34) 6609 (48) 2195 ( 16) 3266 (24) 686 ( 5) 1328 (10) 175 ( 1 52) 7358 (69) 2864 ( 27) 4075 (38) 944 ( 9) 1792 ( 17) 230 (2) T1 7278 (74) 9892 ( 100) 3628 ( 37) 5219 (53) 1731 ( 17) 2561 (26) 548 ( 6) 1098 (11) 149 (2) T2 3226 ( 60) 5392 ( 100) 1368 ( 25) 2065 (38) 619 ( 11) 909 (17) 190 ( 4) 364 (7) 46 (1) T3 2499 ( 48) 5154 ( 100) 829 ( 16) 1433 (28) 303 ( …”

Section: Discussionunclassified

Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study

Xie

Chen

Deng

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Purpose. To establish an effective and accurate prognostic nomogram for lung adenocarcinoma (LUAD). Patients and Methods. 62,355 LUAD patients from 1975 to 2016 enrolled in the Surveillance, Epidemiology, and End Results (SEER) database were randomly and equally divided into the training cohort (n = 31,179) and the validation cohort (n = 31,176). Univariate and multivariate Cox regression analyses screened the predictive effects of each variable on survival. The concordance index (C-index), calibration curves, receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC) were used to examine and validate the predictive accuracy of the nomogram. Kaplan–Meier curves were used to estimate overall survival (OS). Results. 10 prognostic factors associated with OS were identified, including age, sex, race, marital status, American Joint Committee on Cancer (AJCC) TNM stage, tumor size, grade, and primary site. A nomogram was established based on these results. C-indexes of the nomogram model reached 0.777 (95% confidence interval (CI), 0.773 to 0.781) and 0.779 (95% CI, 0.775 to 0.783) in the training and validation cohorts, respectively. The calibration curves were well-fitted for both cohorts. The AUC for the 3- and 5-year OS presented great prognostic accuracy in the training cohort (AUC = 0.832 and 0.827, respectively) and validation cohort (AUC = 0.835 and 0.828, respectively). The Kaplan–Meier curves presented significant differences in OS among the groups. Conclusion. The nomogram allows accurate and comprehensive prognostic prediction for patients with LUAD.

show abstract

“…8 EGFR is the main driver gene in Asian patients, mostly in non-smoking, female, adenocarcinoma patients. 9 The discovery of EGFR tyrosine kinase inhibitor (EGFR-TKI) has revolutionized the traditional treatment of advanced NSCLC. 10 The effect achieved by chemotherapy alone is not significant in clinical treatment, while EGFR-TKI targeted therapy can effectively control tumor progression in the initial EGFR-sensitive advanced lung adenocarcinoma treatment.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma

Zheng

Cui

2022

Eur J Inflamm

View full text Add to dashboard Cite

Objective To assess the clinical efficacy and side effects of EGFR-TKI with or without chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma. Methods A total of 103 IIIB or IV EGFR mutation-positive lung adenocarcinoma patients admitted to the oncology department of Fujian Provincial Hospital from January 2017 to October 2020 were selected. According to genetic mutation status, patients were divided into the following groups: 19del alone, 19del combined with TP53 or other co-mutations, L858R mutation alone, and L858R mutation combined with TP53 or other co-mutations. Targeted drugs or targeted drugs combined with chemotherapy were respectively administered in the four groups. In patients with simple 19 deletion, only targeted drugs with no combined therapy were applied, resulting in seven total groups. The difference between short-term treatment and long-term treatment effects and the occurrence of adverse reactions was calculated and compared. Results There was no statistical significance of difference in the incidence of adverse reactions in seven groups ( p > 0.05). The short-term disease control rate of the combination group was higher than the targeted drug group with the difference yielding statistical significance ( p < 0.001). The short-term objective response rate of the combination group was higher than the targeted drug group, also yielding statistical significance ( p < 0.001). By October 2020, the median progression-free survival (PFS) was 16 months in the EGFR-TKI-targeted combined with chemotherapy group and 10 months in the single-drug EGFR-TKI group, and the PFS time was longer in the combination group than in the single targeted drug group, the difference being statistically significant ( p = 0.001). Conclusions In the treatment of advanced lung adenocarcinoma patients with EGFR-gene sensitive mutations, compared with single EGFR-TKI-targeted therapy, EGFR-TKI-targeted drug combined chemotherapy can control the disease progression more effectively, and does not increase adverse reactions.

show abstract

Gender-specific nomogram models to predict the prognosis of male and female lung adenocarcinoma patients: a population-based analysis

Cited by 7 publications

References 38 publications

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma

Contact Info

Product

Resources

About